Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02676440
Other study ID # ORL-GUM-2101
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 3, 2015
Est. completion date March 14, 2016

Study information

Verified date June 2018
Source Unilever R&D
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a double-blind, randomised, parallel group efficacy study. Up to 240 healthy female and male participants aged over 18 years will participate. There will be two groups of up to 120 participants. Participants will be randomised to the test groups according the allocation table prepared by the Statistician.

Participants will be enrolled on to the study according to the inclusion/exclusion criteria. After enrollment participants will have their teeth that have been allocated for assessment cleaned using a professional prophylaxis polish by the study dentist. The participants will then be provided with a standard cosmetic silica Fluoride toothpaste and a toothbrush to use at home, twice a day for up to four weeks. After this time they will return to the test site and have the baseline dental assessments. Participants will then be randomly allocated to one of the two test products which they will use at home, twice a day for the duration of the study. Dental assessments will be conducted after 13 and 26 weeks of product use at the study site.


Recruitment information / eligibility

Status Completed
Enrollment 222
Est. completion date March 14, 2016
Est. primary completion date December 14, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Be aged 18 years and over, of either gender and in good health.

- Be willing and physically able to carry out all study procedures.

- Be willing and competent (verbally and cognitively) to give written informed consent and complete a medical history form.

- Have at least 20 natural teeth including 5 teeth (excluding 3rd molars) in each quadrant

- Have at least 6 natural teeth assessable teeth in the Upper 4 to 4 region.

- Have a mean Modified Gingival Index (MGI) score of 2 at screening in the Upper 4 to 4 region.

- Not have had a scale and prophylaxis in the month prior to enrolment or have one scheduled prior to the end of the study.

- Be willing to use the test products for 6 months

Exclusion Criteria:

- Current participation in any other cosmetic trials, any dental clinical trials or clinical trials.

- Pregnant or nursing women.

- Medical condition and/or regular use of any medication which might affect the outcome of the study, as determined by the study dentist, principally a course of anti-inflammatory, antimicrobial or statin drugs

- Obvious signs of untreated caries or significant periodontal disease, which in the opinion of the Study Dentist, will affect either the scientific validity of the study or if the participants was to participate in the study would affect their wellbeing.

- Any participant who, in the judgement of the investigator, should not participate in the study.

- Full or partial dentures wearers.

- Current orthodontic treatment.

- Have oral piercings.

- Smokers or those who have a recent smoking history.

- Taking dietary supplements (e.g. multivitamins; antioxidants; fish oils).

- Any subject with a single MGI score of 4 in the any area of the mouth at any time point will be excluded.

- A subject will be excluded from the study if they have a MGI mouth mean of >2.75 at screening

- Any subject with a single MGI score of 3 at Baseline

- Use of non study oral care products, e.g. dental floss, chewing gum, mouth rinses during the pre treatment and test phases of the study.

- The subject is an employee of Unilever or a member of the study team.

- Taking a course of antimicrobial or anti-inflammatory drugs within 4 weeks of screening

- Those taking anti-histamine or anti-inflammatory medication in the 24 hours prior to the dental assessments

- Diabetics

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Treatment
F13/T38
Comparator
M26

Locations

Country Name City State
United Kingdom Bristol Dental Hospital and School Bristol

Sponsors (2)

Lead Sponsor Collaborator
Unilever R&D Bristol Dental School and Hospital

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in gingival condition as assessed using the Modified Lobene Gingival Index 13 weeks
Primary Change in gingival condition as assessed using the Saxton and van der Ouderaa bleeding index 13 weeks
Primary Change in gingival condition as assessed using the Modified Quigley and Hein plaque index 13 weeks
Secondary Change in gingival condition as assessed using the Modified Lobene Gingival Index 26 weeks
Secondary Change in gingival condition as assessed using the Saxton and van der Ouderaa bleeding index 26 weeks
Secondary Change in gingival condition as assessed using the Modified Quigley and Hein plaque index 26 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1